EGF Receptor in Breast Cancer Chemoresistance

  • Robert B. Dickson
  • T. B. Deb
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 608)


Acquisition of resistance of breast cancer to chemotherapy is commonly associated with progression of the disease to increased metastatic spread. Although early studies on this problem examined the possible roles of chemotherapy drug metabolism and efflux by resistant breast cancer cells, more recent work has implicated aberrant growth factor receptor and signal transduction pathways in the process for such commonly used drugs as the anthracyclines. Cell mutability, DNA repair defects, and loss of DNA damage checkpoint controls certainly must play key roles in the ability of cancer cells to evolve such resistance mechanisms.1,2


Breast Cancer Epidermal Growth Factor Receptor Clin Oncol Pleckstrin Homology Domain Mouse Mammary Epithelial Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Dickson RB, Lippman ME. Drug and Hormonal Resistance in Breast Cancer: Cellular and Molecular Mechanisms. New York: Ellis Horwood, 1995:1–440.Google Scholar
  2. 2.
    Dickson RB, Pestell RG, Lippman ME. Molecular biology of breast cancer. In: DeVita V, Hellman S, Rosenberg S, eds. Cancer: Principles and Practice of Oncology. 7th ed. Philadelphia: JB Lippincott, 2005:1399–1414.Google Scholar
  3. 3.
    Siegel PM, Muller WJ. Tyrosine kinase and signal transduction in mouse mammary tumorigenesis. In: Dickson RB, Solomon DS, eds. Hormones and Growth Factors in Development and Neoplasia. New York: Wily Liss, 1999:397–419.Google Scholar
  4. 4.
    Nicholson S, Halcrow P, Sainsbury JR et al. Epidermal growth factor receptor (EGFr) status associated with failure of primary endocrine therapy in elderly postmenopausal patients with breast cancer. Br J Cancer 1988; 58:810–814.PubMedGoogle Scholar
  5. 5.
    Nicholson S, Sainsbury JR, Halcrow P et al. Expression of epidermal growth factor receptors associated with lack of response to endocrine therapy in recurrent breast cancer. Lancet 1989; 28:182–185.CrossRefGoogle Scholar
  6. 6.
    Nicholson S, Richard J, Sainsbury C et al. Epidermal growth factor receptor (EGFr); results of a 6 year follow-up study in operable breast cancer with emphasis on the node negative subgroup. Br J Cancer 1991; 63:146–150.PubMedGoogle Scholar
  7. 7.
    Pegram MD, Slamon DJ. Combination therapy with trastuzumab (Herceptin) and cisplatin for chemoresistant metastatic breast cancer: Evidence for receptor-enhanced chemosensitivity. Semin Oncol 1999; 26:89–95.PubMedGoogle Scholar
  8. 8.
    Hayes DF. Prognostic and predictive factors for breast cancer: Translating technology to oncology. J Clin Oncol 2005; 23:1596–1599.CrossRefPubMedGoogle Scholar
  9. 9.
    Pegram MD, Pietras R, Bajamonde A et al. Targeted therapy: Wave of the future. J Clin Oncol 2005; 23:1776–1781.CrossRefPubMedGoogle Scholar
  10. 10.
    Mitsuuchi Y, Johnson SW, Selvakumaran M et al. The phosphatidylinositol 3-kinase/AKT signal transduction pathway plays a critical role in the expression of p21WAF1/CIP1/SDI1 induced by cisplatin and paclitaxel. Cancer Res 2002; 60:5390–5394.Google Scholar
  11. 11.
    Kim D, Dan HC, Park S et al. AKT/PKB signaling mechanisms in cancer and chemoresistance. Front Biosci 2005; 10:975–987.CrossRefPubMedGoogle Scholar
  12. 12.
    Yu D. Mechanisms of ErbB2-mediated pactitaxel resistance and trastuzumab-mediated paclitaxel sensitization in ErbB2-overexpressing breast cancers. Semin Oncol 2001; 28:12–17.CrossRefPubMedGoogle Scholar
  13. 13.
    Jin W, Wu L, Liang K et al. Roles of the PI-3K and MEK pathways in Ras-mediated chemoresistance in breast cancer cells. Br J Cancer 2003; 89:185–191.CrossRefPubMedGoogle Scholar
  14. 14.
    Knuefermann C, Lu Y, Liu B et al. HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells. Oncogene 2003; 22:3205–3212.CrossRefPubMedGoogle Scholar
  15. 15.
    Yano S, Tokumitsu H, Soderling TR. Calcium promotes cell survival through CaM-K kinase activation of the protein-kinase-B pathway. Nature 1998; 396:584–587.CrossRefPubMedGoogle Scholar
  16. 16.
    Datta SR, Brunet A, Greenberg ME. Cellular survival: A play in three Akts. Genes Dev 1999; 13:2905–2927.CrossRefPubMedGoogle Scholar
  17. 17.
    Datta K, Bellacosa A, Chan TO et al. Akt is a direct target of the phosphatidylinositol 3-kinase. Activation by growth factors, v-src and v-Ha-ras, in Sf9 and mammalian cells. J Biol Chem 1996; 271:30835–30839.CrossRefPubMedGoogle Scholar
  18. 18.
    Filippa N, Sable CL, Filloux C et al. Mechanism of protein kinase B activation by cyclic AMP-dependent protein kinase. Mol Cell Biol 1999; 19:4989–5000.PubMedGoogle Scholar
  19. 19.
    Cantley LC. The phosphoinositide 3-kinase pathway. Science 2002; 296:1655–1657.CrossRefPubMedGoogle Scholar
  20. 20.
    Ahmed NN, Grimes HL, Bellacosa A et al. Transduction of interleukin-2 antiapoptotic and proliferative signals via Akt protein kinase. Proc Natl Acad Sci USA 1997; 94:3627–3632.CrossRefPubMedGoogle Scholar
  21. 21.
    Yao R, Cooper GM. Requirement for phosphatidylinositol-3 kinase in the prevention of apoptosis by nerve growth factor. Science 1995; 267:2003–2006.CrossRefPubMedGoogle Scholar
  22. 22.
    Valius M, Kazlauskas A. Phospholipase C-gamma 1 and phosphatidylinositol 3 kinase are the downstream mediators of the PDGF receptor’s mitogenic signal. Cell 1993; 73:321–334.CrossRefPubMedGoogle Scholar
  23. 23.
    Auger KR, Serunian LA, Soltoff SP et al. PDGF-dependent tyrosine phosphorylation stimulates production of novel polyphosphoinositides in intact cells. Cell 1989; 57:167–175.CrossRefPubMedGoogle Scholar
  24. 24.
    Kimura K, Hattori S, Kabuyama Y et al. Neurite outgrowth of PC12 cells is suppressed by wortmannin, a specific inhibitor of phosphatidylinositol 3-kinase. J Biol Chem 1994; 269:18961–18967.PubMedGoogle Scholar
  25. 25.
    Kaliman P, Vinals F, Testar X et al. Phosphatidylinositol 3-kinase inhibitors block differentiation of skeletal muscle cells. J Biol Chem 1996; 271:19146–19151.CrossRefPubMedGoogle Scholar
  26. 26.
    Rodriguez-Viciana P, Warne PH, Khwaja A et al. Role of phosphoinositide 3-OH kinase in cell transformation and control of the actin cytoskeleton by Ras. Cell 1997; 89:457–467.CrossRefPubMedGoogle Scholar
  27. 27.
    Kamohara S, Hayashi H, Todaka M et al. Platelet-derived growth factor triggers translocation of the insulin-regulatable glucose transporter (type 4) predominantly through phosphatidylinositol 3-kinase binding sites on the receptor. Proc Natl Acad Sci USA 1995; 92:1077–1081.CrossRefPubMedGoogle Scholar
  28. 28.
    Clarke JF, Young PW, Yonezawa K et al. Inhibition of the translocation of GLUT1 and GLUT4 in 3T3-L1 cells by the phosphatidylinositol 3-kinase inhibitor, wortmannin. Biochem J 1994; 300:631–635.PubMedGoogle Scholar
  29. 29.
    Wennstrom S, Siegbahn A, Yokote K et al. Membrane ruffling and chemotaxis transduced by the PDGF beta-receptor require the binding site for phosphatidylinositol 3′ kinase. Oncogene 1994; 9:651–660.PubMedGoogle Scholar
  30. 30.
    James SR, Downes CP, Gigg R et al. Specific binding of the Akt-1 protein kinase to phosphatidylinositol 3,4,5-trisphosphate without subsequent activation. Biochem J 1996; 315:709–713.PubMedGoogle Scholar
  31. 31.
    Frech M, Andjelkovic M, Ingley E et al. High affinity binding of inositol phosphates and phosphoinositides to the pleckstrin homology domain of RAC/protein kinase B and their influence on kinase activity. J Biol Chem 1997; 272:8474–8481.CrossRefPubMedGoogle Scholar
  32. 32.
    Franke TF, Yang SI, Chan TO et al. The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase. Cell 1995; 81:727–736.CrossRefPubMedGoogle Scholar
  33. 33.
    Alessi DR, Andjelkovic M, Caudwell B et al. Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO J 1996; 15:6541–6551.PubMedGoogle Scholar
  34. 34.
    Egea J, Espinet C, Soler RM et al. Neuronal survival induced by neurotrophins requires calmodulin. J Cell Biol 2001; 154:585–597.CrossRefPubMedGoogle Scholar
  35. 35.
    Cheng A, Wang S, Yang D et al. Calmodulin mediates brain-derived neurotrophic factor cell survival signaling upstream of Akt kinase in embryonic neocortical neurons. J Biol Chem 2003; 278:7591–7599.CrossRefPubMedGoogle Scholar
  36. 36.
    Yang C, Watson RT, Elmendorf JS et al. Calmodulin antagonists inhibit insulin-stimulated GLUT4 (glucose transporter 4) translocation by preventing the formation of phosphatidylinositol 3,4,5-trisphosphate in 3T3L1 adipocytes. Mol Endocrinol 2000; 14:317–326.CrossRefPubMedGoogle Scholar
  37. 37.
    Fischer R, Julsgart J, Berchtold MW. High affinity calmodulin target sequence in the signalling molecule PI 3-kinase. FEBS Lett 1998; 425:175–177.CrossRefPubMedGoogle Scholar
  38. 38.
    Ichikawa J, Furuya K, Miyata S et al. EGF enhances Ca(2+) mobilization and capacitative Ca(2+) entry in mouse mammary epithelial cells. Cell Biochem Funct 2000; 18:215–225.CrossRefPubMedGoogle Scholar
  39. 39.
    Ichikawa J, Kiyohara T. Suppression of EGF-induced cell proliferation by the blockade of Ca2+ mobilization and capacitative Ca2+ entry in mouse mammary epithelial cells. Cell Biochem Funct 2001; 19:213–219.CrossRefPubMedGoogle Scholar
  40. 40.
    Ramljak D, Coticchia CM, Nishanian TG et al. Epidermal growth factor inhibition of c-Myc-mediated apoptosis through Akt and Erk involves Bcl-xL upregulation in mammary epithelial cells. Exp Cell Res 2003; 287:397–410.CrossRefPubMedGoogle Scholar
  41. 41.
    Deb TB, Coticchia CM, Dickson RB. Calmodulin-mediated activation of Akt regulates survival of c-Myc-overexpressing mouse mammary carcinoma cells. J Biol Chem 2004; 279:38903–38911.CrossRefPubMedGoogle Scholar
  42. 42.
    Kau TR, Schroeder F, Ramaswamy S et al. A chemical genetic screen identifies inhibitors of regulated nuclear export of a Forkhead transcription factor in PTEN-deficient tumor cells. Cancer Cell 2003; 463–476.Google Scholar
  43. 43.
    Shen X, Valencia CA, Szostak J et al. Scanning the human proteome for calmodulin-binding proteins. Proc Natl Acad Sci USA 2005; 102:5969–5974.CrossRefPubMedGoogle Scholar
  44. 44.
    Schmidt M, Lichtner RB. EGF receptor targeting in therapy-resistant human tumors. Drug Resist Updat 2002; 5:11–18.CrossRefPubMedGoogle Scholar
  45. 45.
    Harris TK. PDK1 and PKB/Akt: Ideal targets for development of new strategies to structure based drug design. IUBMB Life 2003; 55:117–1126.CrossRefPubMedGoogle Scholar
  46. 46.
    Ennis BW, Valverius E, Bates SE et al. Anti-EGF receptor antibodies inhibit the autocrine stimulated growth of MDA-MB-468 human breast cancer cells. Molec Endocrinol 1989; 3:1830–1838.CrossRefGoogle Scholar
  47. 47.
    Baselga J, Arteaga CL. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol 2005; 23:2445–2459.CrossRefPubMedGoogle Scholar
  48. 48.
    Spector NL, Xia W, Burris IIIrd H et al. Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. J Clin Oncol 2005; 23:2502–2512.CrossRefPubMedGoogle Scholar
  49. 49.
    Agus DB, Gordon MS, Taylor C et al. Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. J Clin Oncol 2005; 23:2534–2543.CrossRefPubMedGoogle Scholar
  50. 50.
    Blumenthal RD. Chemosensitivity Volume 1: In Vitro Assays. Totowa: Human Press, 2005: 1–231.Google Scholar
  51. 51.
    Blumenthal RD. Chemosensitivity Volume 2: In Vitro Models, Imaging, and Molecular Regulators. Totowa: Human Press, 2005:1–442.Google Scholar

Copyright information

© Landes Bioscience and Springer Science+Business Media 2007

Authors and Affiliations

  1. 1.Georgetown University Medical CenterWashington, DCUSA

Personalised recommendations